期刊文献+

老年女性骨质疏松症患者静脉滴注唑来膦酸注射液急性期反应观察 被引量:8

Observation on Acute-phase Reaction of Zoledronic Acid Injection in Elder Osteoporotic Women
下载PDF
导出
摘要 目的:观察老年女性骨质疏松症(OP)患者静滴唑来膦酸后急性期反应(APR)的发生情况。方法:47例老年女性OP患者静滴唑来膦酸注射液5 mg后,记录她们在72 h内发热、肌痛、流感样症状、头痛头晕、恶心呕吐等APR的发生情况。结果:35例(74.47%)患者出现1个或1个以上的APR,其中发热19例(40.43%),肌痛18例(38.30%),流感样症状14例(29.79%),头痛头晕13例(27.66%),恶心呕吐12例(25.53%)。发热患者伴随其他APR的平均个数(3.35±1.41)个明显高于不发热的患者的平均个数(1.40±0.63)个,差异有统计学意义(P<0.01)。且在发热患者中,最高体温与其他APR间具有相关性(r=0.577,P<0.05)。结论:老年女性OP患者静脉输注唑来膦酸后,易出现发热等APR,应重视静脉输注后的观察和处理。 Objective: To investigate the incidence of acute-phase reaction( APR) of zoledronic acid injection in elder osteoporotic women. Methods: APR( ≤72h after 5 mg zoledronic acid injection infusion),including fever,myalgia,influenza-like symptoms,headache,dizziness,nausea and vomiting,were recorded. Results: 35( 74. 47%) cases had one or more APR,and the most common APR was fever( 40. 43%),followed by myalgia( 38. 30%),influenza-like symptoms( 29. 79%),headache and dizziness( 27. 66%),nausea and vomiting( 25. 53%). There was a significant difference in the average number of other APR observed between subjects presented with fever( 3. 35 ± 1. 41) and those without( 1. 40 ±0. 63)( P〈0. 01). Moreover,the higher body temperature were correlated to more incidences of other APR in feverish cases( P〈0. 05). Conclusion: There was a high incidence of APR in older osteoporotic women after treatment with zoledronic acid injection,as a result,close observation and proper treatment should be implemented to secure the safety of the patients.
出处 《药物流行病学杂志》 CAS 2016年第7期432-434,共3页 Chinese Journal of Pharmacoepidemiology
基金 浙江省医药卫生平台重点资助项目(编号:2016ZDAD02) 浙江省人民医院优秀青年人员科研启动基金(编号:zry2015C002)
关键词 唑来膦酸 骨质疏松症 急性期反应 发热 Zoledronic acid Osteoporosis Adverse-phase reaction Fever
  • 相关文献

参考文献6

  • 1原发性骨质疏松症诊治指南(2011年)[J].中华骨质疏松和骨矿盐疾病杂志,2011,4(1):2-17. 被引量:1831
  • 2A1-Agha AE, Hayatalhazmi RS. Osteopomsis treatment with zoledronic acid in pediatric population at a university hospital in Western Saudi Arabia. A 13-year experience[J]. Saudi Med J,2015,36( ll ) :1312-1318.
  • 3Black DM, Delmas PD, Eastell R, et al. Once-yearly zole- dronic acid for treatment of postmenopausal osteoporosis[ J]. N Engl J Meal,2007,356( 18 ) : 1809-1822.
  • 4Welton JL, Morgan MP, Marti S,et al. Monocytes and γδ T cells control the acute-phase response to intravenous zoledr- onate: insights from a phase IV safety trial[ J]. J Bone Miner Res ,2013,28 ( 3 ) :464-471.
  • 5樊国斌,李素娟,沈钦华.2011~2013年我院497例药品不良反应报告分析[J].药物流行病学杂志,2016,25(3):166-169. 被引量:6
  • 6Patel DV, Bolland M, Nisa Z, et al. Incidence of ocular side effects with intravenous zoledronate: secondary analysis of a randomized controlled trial [ J ]. Osteoporos Int, 2015,26 (2) :499-503.

二级参考文献6

共引文献1835

同被引文献49

引证文献8

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部